Roche pushes late-comer Tecentriq as new liver cancer option

Roche's Tecentriq mixed with Avastin helped liver cancer patients live longer, a boost to the Swiss drugmaker's strategy of expanding its late-to-the-game immunotherapy into niche areas not yet dominated by rivals.

from Reuters: Health News https://ift.tt/32IH0LP
via IFTTT